Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 608 (ZNF608) is a member of the C2H2-type zinc finger protein family, functioning predominantly as a transcription factor involved in the negative regulation of transcription by RNA polymerase II[1][3][4][6][7]. ZNF608 specifically represses the transcription of the gene ZNF609[3][4][7]. It is predicted to act in the nucleus and binds metal ions (notably zinc) as part of its structural motif[2][4]. Recent research implicates ZNF608 in cancer biology, where it is a direct regulatory target of miR-21-3p—a microRNA associated with promoting cancer cell proliferation, invasion, and chemoresistance in ovarian and prostate tumors[1]. The gene is also known by several aliases, including NY-REN-36 and is expressed as a protein-coding gene on human chromosome 5[3][4][6][7]. Although ZNF608 participates in functional gene regulation, there are currently no clinically approved drugs or direct therapeutic modalities reported to target this protein, nor is it classified as a clinically actionable therapeutic target at this time[1][3][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 608 (ZNF608).